Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...

At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...

Medtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.

Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...

The cryptocurrency market faced a sharp sell-off on Monday, with Bitcoin plunging to an intraday low of $80,000 and Ethereum ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Medtronic plc , a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides interventional cardiologists, cardiothoracic surgeons, and heart teams with ...